TG Therapeutics, Inc. $TGTX Stake Cut by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 47.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,323 shares of the biopharmaceutical company’s stock after selling 34,641 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in TG Therapeutics were worth $1,384,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. raised its stake in TG Therapeutics by 44.2% during the third quarter. Victory Capital Management Inc. now owns 152,778 shares of the biopharmaceutical company’s stock worth $5,519,000 after acquiring an additional 46,795 shares during the period. Rafferty Asset Management LLC raised its position in shares of TG Therapeutics by 12.7% during the 3rd quarter. Rafferty Asset Management LLC now owns 212,058 shares of the biopharmaceutical company’s stock worth $7,661,000 after purchasing an additional 23,838 shares during the period. Handelsbanken Fonder AB lifted its holdings in shares of TG Therapeutics by 17.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 47,500 shares of the biopharmaceutical company’s stock worth $1,716,000 after purchasing an additional 6,900 shares during the last quarter. DNB Asset Management AS lifted its holdings in shares of TG Therapeutics by 32.1% in the 3rd quarter. DNB Asset Management AS now owns 13,905 shares of the biopharmaceutical company’s stock worth $502,000 after purchasing an additional 3,378 shares during the last quarter. Finally, Optiver Holding B.V. grew its stake in TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 732 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock opened at $29.03 on Friday. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $46.48. The company has a current ratio of 4.10, a quick ratio of 2.89 and a debt-to-equity ratio of 0.38. The stock has a market cap of $4.64 billion, a PE ratio of 10.48 and a beta of 1.87. The company’s 50-day moving average price is $29.70 and its two-hundred day moving average price is $31.46.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The business had revenue of $192.57 million during the quarter, compared to analyst estimates of $192.15 million. During the same period in the prior year, the firm earned $0.15 EPS. The business’s revenue for the quarter was up 78.0% on a year-over-year basis. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on TGTX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. The Goldman Sachs Group increased their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. JPMorgan Chase & Co. dropped their price target on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Finally, Wall Street Zen cut TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

Trending Headlines about TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Company set FY2026 revenue guidance of approximately $875–$900 million, well above the consensus of ~$785 million, signaling stronger-than-expected sales/market uptake that could support valuation and near-term cash flow. (No EPS guidance was supplied alongside the revenue range.)
• Positive Sentiment: TG Therapeutics scheduled multiple BRIUMVI® (ublituximab) data presentations for relapsing MS at the American Academy of Neurology (AAN) 2026 meeting (Apr 18–22). New clinical or safety details released at AAN could serve as a catalyst for shares. TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at AAN 2026
• Neutral Sentiment: The company’s most recent quarterly report showed revenue roughly in line with estimates but an EPS miss (reported $0.14 vs. $0.35 consensus), and management did not provide explicit EPS guidance with the FY2026 revenue range — leaving clarity on near-term profitability limited.
• Negative Sentiment: HC Wainwright trimmed EPS forecasts across several periods (Q2 and Q3 2026 and FY2026–FY2030), lowering near- and longer-term profit expectations (e.g., FY2026 from $1.30 to $1.21 and small downgrades for FY2027–FY2030). These cuts can weigh on sentiment and compress upside until company results or clinical readouts confirm the revenue trajectory. Q4 EPS Estimates for TG Therapeutics Cut by HC Wainwright

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.